Marinus Pharmaceuticals Future Growth
Future criteria checks 5/6
Marinus Pharmaceuticals is forecast to grow earnings and revenue by 66.2% and 26.3% per annum respectively while EPS is expected to grow by 71.3% per annum.
Key information
66.2%
Earnings growth rate
71.3%
EPS growth rate
| Pharmaceuticals earnings growth | 19.8% |
| Revenue growth rate | 26.3% |
| Future return on equity | n/a |
| Analyst coverage | Good |
| Last updated | 03 Jan 2025 |
Recent future growth updates
Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Consensus Forecasts Have Become A Little Darker Since Its Latest Report
Aug 16
Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Just Reported, And Analysts Assigned A US$8.00 Price Target
May 11Recent updates
A Piece Of The Puzzle Missing From Marinus Pharmaceuticals, Inc.'s (NASDAQ:MRNS) Share Price
Sep 20Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Consensus Forecasts Have Become A Little Darker Since Its Latest Report
Aug 16Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Just Reported, And Analysts Assigned A US$8.00 Price Target
May 11Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Might Not Be As Mispriced As It Looks After Plunging 86%
Apr 16Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Analysts Are Cutting Their Estimates: Here's What You Need To Know
Mar 08Does Marinus Pharmaceuticals (NASDAQ:MRNS) Have A Healthy Balance Sheet?
Dec 22Is Marinus Pharmaceuticals (NASDAQ:MRNS) Using Debt Sensibly?
Sep 22Why Investors Shouldn't Be Surprised By Marinus Pharmaceuticals, Inc.'s (NASDAQ:MRNS) P/S
Jun 12Forecast: Analysts Think Marinus Pharmaceuticals, Inc.'s (NASDAQ:MRNS) Business Prospects Have Improved Drastically
May 16Analysts Just Made A Major Revision To Their Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Revenue Forecasts
Oct 26Is Marinus Pharmaceuticals (NASDAQ:MRNS) Weighed On By Its Debt Load?
Oct 12Marinus Pharmaceuticals: Positive News Flow Of Note
Sep 22Marinus Pharma closes on sale of a U.S. FDA priority review voucher for $110M
Aug 29Analysts' Revenue Estimates For Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Are Surging Higher
Aug 13Marinus Pharmaceuticals Q2 2022 Earnings Preview
Aug 10Marinus Pharma announces U.S. commercial launch of seizure therapy Ztalmy
Jul 28Revisiting Marinus Pharmaceuticals
May 05Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2027 | 96 | 8 | N/A | N/A | 5 |
| 12/31/2026 | 74 | -18 | N/A | N/A | 5 |
| 12/31/2025 | 54 | -40 | 7 | 7 | 7 |
| 12/31/2024 | 35 | -118 | -101 | -100 | 6 |
| 9/30/2024 | 31 | -140 | -116 | -115 | N/A |
| 6/30/2024 | 30 | -149 | -121 | -120 | N/A |
| 3/31/2024 | 28 | -145 | -114 | -114 | N/A |
| 12/31/2023 | 31 | -141 | -118 | -118 | N/A |
| 9/30/2023 | 31 | -134 | -113 | -113 | N/A |
| 6/30/2023 | 26 | -29 | -119 | -117 | N/A |
| 3/31/2023 | 22 | -35 | -128 | -127 | N/A |
| 12/31/2022 | 25 | -20 | -115 | -113 | N/A |
| 9/30/2022 | 20 | -14 | -115 | -113 | N/A |
| 6/30/2022 | 28 | -105 | -80 | -78 | N/A |
| 3/31/2022 | 28 | -91 | -69 | -67 | N/A |
| 12/31/2021 | 15 | -99 | -58 | -55 | N/A |
| 9/30/2021 | 15 | -88 | -52 | -50 | N/A |
| 6/30/2021 | 5 | -84 | -71 | -70 | N/A |
| 3/31/2021 | 4 | -76 | -63 | -63 | N/A |
| 12/31/2020 | 2 | -76 | -61 | -61 | N/A |
| 9/30/2020 | 0 | -74 | -61 | -61 | N/A |
| 6/30/2020 | N/A | -72 | -58 | -58 | N/A |
| 3/31/2020 | N/A | -69 | -51 | -51 | N/A |
| 12/31/2019 | N/A | -54 | -49 | -49 | N/A |
| 9/30/2019 | N/A | -49 | -42 | -42 | N/A |
| 6/30/2019 | N/A | -46 | -37 | -36 | N/A |
| 3/31/2019 | N/A | -43 | -34 | -33 | N/A |
| 12/31/2018 | N/A | -37 | -28 | -28 | N/A |
| 9/30/2018 | N/A | -31 | -23 | -23 | N/A |
| 6/30/2018 | N/A | -24 | N/A | -19 | N/A |
| 3/31/2018 | N/A | -19 | N/A | -18 | N/A |
| 12/31/2017 | N/A | -19 | N/A | -19 | N/A |
| 9/30/2017 | N/A | -20 | N/A | -20 | N/A |
| 6/30/2017 | N/A | -22 | N/A | -24 | N/A |
| 3/31/2017 | N/A | -27 | N/A | -26 | N/A |
| 12/31/2016 | N/A | -29 | N/A | -25 | N/A |
| 9/30/2016 | N/A | -30 | N/A | -24 | N/A |
| 6/30/2016 | N/A | -29 | N/A | -23 | N/A |
| 3/31/2016 | N/A | -25 | N/A | -22 | N/A |
| 12/31/2015 | N/A | -25 | N/A | -20 | N/A |
| 9/30/2015 | N/A | -21 | N/A | -17 | N/A |
| 6/30/2015 | N/A | -18 | N/A | -14 | N/A |
| 3/31/2015 | N/A | -17 | N/A | -11 | N/A |
| 12/31/2014 | N/A | -13 | N/A | -9 | N/A |
| 9/30/2014 | N/A | -12 | N/A | -10 | N/A |
| 6/30/2014 | N/A | -12 | N/A | -8 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: MRNS is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.6%).
Earnings vs Market: MRNS is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: MRNS is expected to become profitable in the next 3 years.
Revenue vs Market: MRNS's revenue (26.3% per year) is forecast to grow faster than the US market (9% per year).
High Growth Revenue: MRNS's revenue (26.3% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if MRNS's Return on Equity is forecast to be high in 3 years time
Discover growth companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/21 22:12 |
| End of Day Share Price | 2025/01/17 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Marinus Pharmaceuticals, Inc. is covered by 15 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Brian Skorney | Baird |
| François Brisebois | Craig-Hallum Capital Group LLC |
| Douglas Tsao | H.C. Wainwright & Co. |